Abstract
Quality control and quality assurance procedures are discussed for the agreed benchmark standard Freund’s complete adjuvant (FCA). In addition, the use of the incomplete adjuvant (FIA) in the preparation of antisera is discussed. A major problem is the use of a safe and suitable mineral oil in FCA and FIA; manufacturers should provide infra-red spectra and gas liquid chromatography analyses. A range of safety tests, toxicity, pyrogenicity and endotoxin assays and advice on practical procedures for the use of these adjuvants are described.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lewis, P. A., Loomis, D. (1924) Allergic irritability. The formation of anti-sheep hemolytic amboceptor in the normal and tuberculous guinea-pig. J Exp Med 40, 503–515.
Lewis, P. A., Loomis, D. (1926) Allergic irritability. III. The influence of chronic infections and of trypan blue on the formation of specific antibodies. J Exp Med 43, 263–273.
Dienes, L., Schoenheit, E. W. (1927) Local hypersensitiveness I. Sensitization of tuberculous guinea-pigs with egg-white and timothy pollen. J Immunol 14, 9–42.
Dienes, L. (1929) The technique of producing the tuberculin type of sensitisation with egg-white in tuberculous guinea-pigs. J Immunol 17, 531–538.
Stewart-Tull, D. E. S., Brown, F. (1993) First steps towards an international harmonization of veterinary biologicals. Vaccine 11, 692–695.
Robbins, J. (1980) in (Mizrahi, A., et al., eds.) New Developments with Human and Veterinary Vaccines. AR Liss Inc., New York, pp 393–394.
Salk, J. E., Bailey, M. L., Laurent, A. (1952) Use of adjuvants in studies on influenza immunization, increased antibody formation in human subjects inoculated with influenza virus vaccine in water-in-oil emulsion. Am J Hyg 55, 439–456.
Davenport, F. M., Hennessy, A. V., Houser, H. B., Cryns, W. F. (1956) Evaluation of adjuvant influenza virus vaccine tested against influenza B, 1954–1955. Am J Hyg 64, 304–313.
Bell, J. A., Philip, R. N., Davis, D. J., Beem, M. O., Beigelman, P. M., Engler, J. I., Mellin, G. W., Johnson, J. H., Lerner, A. M. (1961) Epidemiologic studies on influenza in familial and general populations, 1951–1956: IV vaccine reactions. Am J Hyg 73, 148–163.
Davenport, F. M. (1968) Seventeen years experience with mineral oil adjuvant influenza virus vaccines. Ann Allergy 26, 288–292.
Stewart-Tull., D. E. S. (2003) Adjuvant formulations for experimental vaccines, in (Robinson, A., Hudson, M. J., Cranage, M. P., eds.) Vaccine Protocols, 2nd edn. Humana Press, Totowa, NJ.
Cutler, J. C., Lesesne, L., Vaughn, I. (1960) Use of poliomyelitis virus vaccine in light mineral oil adjuvant in a community immunization program and report of reactions encountered. J Allergy 33, 193–209.
Freund, J. (1951) The effect of paraffin oil and mycobacteria on antibody formation and sensitisation. A review. Am J Clin Path 21, 645–656.
White, R. G. (1959) The adjuvant effects of mycobacterial cells and fractions, in (Shaffer, J. H., Lo Grippo, G. A., Chase, M. W., eds.) Mechanisms of Hypersensitivity. Churchill, London, pp 637–645.
Suter, E., White, R. G. (1954) Response of reticulo-endothelial system to injection of ‘purified wax’ and lipopolysaccharide of tubercle bacilli; a histologic and immunogenic study. Am Rev Tuberc 70, 793–805.
Paraf, A. (1970) Mechanisme d’action des adjuvants de l’immunite. Annales des l’Institut Pasteur 118, 419–441.
MacLennan, R., Schofield, F. D., Pittman, M., Hardegree, M. C., Barile, M. F. (1965) Immunization against neonatal tetanus in New Guinea. Antitoxin response of pregnant women to adjuvant and plain toxoids. Bull World Health Org 32, 683.
Stewart-Tull, D. E. S. (1983) Immunologically important constituents of mycobacteria: adjuvants, in (Ratledge, C., Stanford J., eds.) The Biology of the Mycobacteria. Academic Press, London, pp 3–84.
White, R. G. (1959) The adjuvant effects of mycobacterial cells and fractions, in (Lo Grippo, G. A., Chase, M. W., eds.) Mechanisms of Hypersensitivity. Churchill, London, pp 637–645.
Lederer, E. (1971) The mycobacterial cell wall. Pure Appl Chem 25, 135–165.
Stewart-Tull, D. E. S. (1989) Recommendations for the assessment of adjuvants (immunopotentiators), in (Gregoriadis, G., Allison, A. C., Poste, G., eds.) Immunological Adjuvants and Vaccines. Plenum Press, London, pp 213–226.
Stewart-Tull, D. E. S. (1985) Immunopotentiating activity of peptidoglycan and surface polymers, in (Stewart-Tull, D. E. S., Davies, M., eds.) Immunology of the Bacterial Cell Envelope. John Wiley & Sons Ltd., Sussex, pp 47–89.
Stewart-Tull, D. E. S. (1995) Freund-type mineral oil adjuvant emulsions, in (Stewart-Tull, D. E. S., ed.) The Theory and Practical Application of Adjuvants. John Wiley & Sons, Chichester, pp 1–19.
Stewart-Tull, D. E. S., Shimono, T., Kotani, S., Knights, B. A. (1976) Immuno-suppressive effect in mycobacterial adjuvant emulsions of mineral oils containing low molecular weight hydrocarbons. Int Arch Allergy Appl Immunol 52, 118–128.
Stewart-Tull, D. E. S., Rowe, R. E. C. (1975) Procedures for large-scale antiserum production in sheep. J Immunol Methods 8, 37–46.
Stewart-Tull, D. E. S. (1989) Recommendations for the assessment of adjuvants, in (Gregoriadis, G., Allison, A. C., Poste, G., eds.) Immunological Adjuvants and Vaccines. NATO ASI Series A: Life Sciences, Plenum, New York, vol 179, pp 213–226.
Stewart-Tull, D. E. S. (1991) The assessment and use of adjuvants, in (Gregoriadis, G., Allison, A. C., Poste, G., eds.) Vaccines Recent Trends and Progress. NATO ASI Series A: Life Sciences, Plenum, New York, vol 215, pp 85–92.
Gray, J. E., Weaver, R. N., Moran, J., Feenstra, E. S. (1974) The parental toxicity of clindamycin-2-phosphate in laboratory animals. Toxicol Appl Pharmacol 27, 308.
British Standards Institution. (1990) Evaluation of medical devices for biological hazards. Part 11. Method of test for haemolysis. Br Stand 5736, 11.
British Standards Institution. (1990) Evaluation of medical devices for biological hazards. Part 5. Method of test for systemic toxicity; assessment of pyrogenicity in rabbits of extracts from medical devices. Br Stand 5736, 5.
Wardlaw, A. C., McCartney, A. C. (1985) Endotoxic activities of lipopolysaccharides, in (Stewart-Tull, D. E. S., Davies, M., eds.) Immunology of the Bacterial Cell Envelope. John Wiley & Sons, Chichester, pp 203–238.
Christodoulides, M., Sidey, F. M., Parton, R., Stewart-Tull, D. E. S. (1987) Acellular pertussis vaccine prepared by a simple extraction and toxoiding procedure. Vaccine 5, 199–207.
Pearson, C. M. (1956) Development of arthritis, periarthritis and periostitis in rats given adjuvant. Proc Soc Exp Biol Med 91, 95–101.
Kohashi, O., Tanaka, A., Kotani, S. (1980) Arthritis – inducing ability of a synthetic adjuvant, N-acetylmuramyl peptides, and bacterial disaccharide peptides related to different oil vehicles and their composition. Infect Immunol 29, 70–75.
Royal Pharmaceutical Society of Great Britain and British Medical Association. (2008) British National Formulary 14. Immunological Products and Vaccines, pp 651–674.
Stones, P. B. (1979) Self injection of veterinary oil-emulsion vaccines. Br Med J 1, 1627.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Stewart-Tull, D.E. (2010). Freund’s Complete and Incomplete Adjuvants, Preparation, and Quality Control Standards for Experimental Laboratory Animals Use. In: Davies, G. (eds) Vaccine Adjuvants. Methods in Molecular Biology, vol 626. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-585-9_5
Download citation
DOI: https://doi.org/10.1007/978-1-60761-585-9_5
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-584-2
Online ISBN: 978-1-60761-585-9
eBook Packages: Springer Protocols